Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Update on the Evidence Regarding Maintenance Therapy

  • Lee, Jeong Eun (Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine) ;
  • Chung, Chae-Uk (Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine)
  • Received : 2013.10.29
  • Accepted : 2013.11.13
  • Published : 2014.01.30
Download PDF
⟨ Previous Next ⟩

Abstract

Maintenance therapy has emerged as a novel therapeutic paradigm for advanced non-small-cell lung cancer (NSCLC). Maintenance therapy that aims to sustain a clinically favorable state after first-line chemotherapy has two strategies. Switch maintenance therapy entails switching to a new and non-cross-resistant agent in an alternating or sequential manner, on completion of first-line chemotherapy. Continuous maintenance therapy keeps ongoing administration of a component of the current regimen after four to six cycles of chemotherapy, if there is a stable disease, or better response. Both maintenance therapies can be continued, until disease progression. The potential evidence regarding maintenance therapy includes providing the opportunity to receive additional treatment, through sustaining tumor shrinkage, and delayed emergence of tumor-related symptom. Thus far, debates over the parameters used to predict the effectiveness of maintenance therapy, financial burden, and uncertainty of improving the quality of life exist. Despite many debates, maintenance therapy, which is currently recommended, has been disclosed to be beneficial.

Keywords

References

  1. National Comprehensive Cancer Network. NCCN guidelines version 2.2013. Non-small cell lung cancer [Internet]. Fort Washington: National Comprehensive Cancer Network; 2013 [cited 2013 Feb 1]. Available from: http://www.nccn.org/professionals/ physician_gls/pdf/nscl.pdf.
  2. Gerber DE, Schiller JH. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol 2013;31:1009-20. https://doi.org/10.1200/JCO.2012.43.7459
  3. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-33.
  4. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002;20:1335-43. https://doi.org/10.1200/JCO.20.5.1335
  5. Smith IE, O'Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, et al. Duration of chemotherapy in advanced nonsmall- cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-43. https://doi.org/10.1200/JCO.2001.19.5.1336
  6. von Plessen C, Bergman B, Andresen O, Bremnes RM, Sundstrom S, Gilleryd M, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006;95:966-73. https://doi.org/10.1038/sj.bjc.6603383
  7. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003;21:2933-9. https://doi.org/10.1200/JCO.2003.02.563
  8. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155-63. https://doi.org/10.1016/j.lungcan.2006.01.006
  9. Belani CP, Waterhouse DM, Ghazal H, Ramalingam SS, Bordoni R, Greenberg R, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabinecarboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15 Suppl):7506. https://doi.org/10.1200/jco.2010.28.15_suppl.7506
  10. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13:247-55. https://doi.org/10.1016/S1470-2045(12)70063-3
  11. Westeel V, Quoix E, Moro-Sibilot D, Mercier M, Breton JL, Debieuvre D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005;97:499-506. https://doi.org/10.1093/jnci/dji096
  12. Sculier JP, Lafitte JJ, Lecomte J, Alexopoulos CG, Van Cutsem O, Giner V, et al. A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer. Ann Oncol 2007;18:1037-42. https://doi.org/10.1093/annonc/mdm084
  13. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-8. https://doi.org/10.1200/JCO.2008.17.1405
  14. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-smallcell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-40. https://doi.org/10.1016/S0140-6736(09)61497-5
  15. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. https://doi.org/10.1056/NEJMoa061884
  16. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34. https://doi.org/10.1200/JCO.2007.14.5466
  17. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-9. https://doi.org/10.1093/annonc/mdq020
  18. Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-smallcell lung cancer. J Clin Oncol 2009;27:3284-9. https://doi.org/10.1200/JCO.2008.20.8181
  19. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an openlabel randomised phase III trial. Lancet 2009;373:1525-31. https://doi.org/10.1016/S0140-6736(09)60569-9
  20. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911-7. https://doi.org/10.1200/JCO.2009.21.9618
  21. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9. https://doi.org/10.1016/S1470-2045(10)70112-1
  22. Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinumdoublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010;28:753-60. https://doi.org/10.1200/JCO.2009.23.3445
  23. Zhang L, Shenglin M, Song X, Han B, Cheng Y, Huang C, et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) (INFORM; C-TONG 0804). J Clin Oncol 2011;29(15 Suppl):LBA7511.
  24. Gaafar RM, Surmont V, Scagliotti G, Van Klaveren R, Papamichael D, Welch J, et al. A double-blind, randomized, placebocontrolled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). J Clin Oncol 2010;28(15 Suppl):7518. https://doi.org/10.1200/jco.2010.28.15_suppl.7518
  25. Coudert B, Ciuleanu T, Park K, Wu YL, Giaccone G, Brugger W, et al. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol 2012;23:388-94. https://doi.org/10.1093/annonc/mdr125
  26. Gerber DE, Rasco DW, Le P, Yan J, Dowell JE, Xie Y. Predictors and impact of second-line chemotherapy for advanced nonsmall cell lung cancer in the United States: real-world considerations for maintenance therapy. J Thorac Oncol 2011;6:365-71. https://doi.org/10.1097/JTO.0b013e3181fff142
  27. Custodio A, de Castro J. Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions. Crit Rev Oncol Hematol 2012;82:338-60. https://doi.org/10.1016/j.critrevonc.2011.08.003

Cited by

  1. The Possibility of Traditional Chinese Medicine as Maintenance Therapy for Advanced Nonsmall Cell Lung Cancer vol.2014, pp.None, 2014, https://doi.org/10.1155/2014/278917
  2. Quality of Life in Patients with NSCLC Receiving Maintenance Therapy vol.7, pp.2, 2015, https://doi.org/10.3390/cancers7020817
  3. The role of maintenance therapy in the treatment of elderly non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials vol.11, pp.None, 2014, https://doi.org/10.2147/dddt.s145025
  4. Oral Vinorelbine as Switch Maintenance Therapy versus Best Supportive Care in Patients with Advanced Adenocarcinoma Non-Small Cell Lung Cancer EGFR Wild Type vol.10, pp.12, 2019, https://doi.org/10.4236/jct.2019.1012077
  5. Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State vol.14, pp.5, 2019, https://doi.org/10.1007/s11523-019-00665-1